Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.66M | -58.95M | 215.72M | -42.15M | -92.23M |
| Total Depreciation and Amortization | 291.00K | 327.00K | 339.00K | 446.00K | 446.00K |
| Total Amortization of Deferred Charges | 661.00K | 655.00K | 636.00K | 614.00K | 591.00K |
| Total Other Non-Cash Items | 25.17M | 21.25M | 28.19M | 27.20M | 27.37M |
| Change in Net Operating Assets | -105.75M | 22.55M | -136.41M | 18.34M | 10.40M |
| Cash from Operations | -60.97M | -14.18M | 108.47M | 4.45M | -53.41M |
| Capital Expenditure | -- | -108.00K | -148.00K | -49.00K | -8.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -108.00K | -148.00K | -49.00K | -8.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 86.00K | 1.26M | 797.00K | 6.56M | 281.00K |
| Repurchase of Common Stock | -22.00K | 0.00 | -4.00K | 0.00 | -7.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 64.00K | 1.26M | 793.00K | 6.56M | 274.00K |
| Foreign Exchange rate Adjustments | -131.00K | 184.00K | 22.00K | 685.00K | 359.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.03M | -12.84M | 109.14M | 11.64M | -52.79M |